Beyond Air, Inc. Common Stock XAIR
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $10.00 (+123.2% upside)
Key Stats
- Today's Range
- $4.25 – $4.73
- 50-Day Range
- $4.25 – $10.50
- 52-Week Range
- $4.25 – $95.60
- Volume
- 314K shs
- Average Volume
- 94K shs
- Market Cap
- $4.41 million
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 1.55
- Price / Sales
- 0.57
Short Interest
- Short Interest
- 5.73%
- Days to Cover
- 3.92
Financials (TTM)
- Revenue
- $7.69 million
- Net Income
- $-34,410,000
- Net Margin
- -447.64%
- Return on Equity
- -1212.05%
- Debt-to-Equity
- —
About Beyond Air, Inc. Common Stock
Beyond Air Inc a commercial-stage medical device and biopharmaceutical company developing a platform of nitric oxide (NO) generators and delivery systems (the LungFit platform) capable of generating NO from ambient air. Its segments are Beyond Air, Beyond Cancer, and NeuroNos. The company generates majority of revenue from Beyond Air. It has developed the Beyond Air NO generator and delivery system which it call LungFit, a novel and precise delivery system that uses NO generated from ambient air with a novel NO generator, the ionizer. Its product and technology includes LungFitPH.
Related Stocks
Compare head-to-head: XAIR vs SYK·XAIR vs BSX·XAIR vs RMD·XAIR vs BAX
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.